You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the SUFLAVE (magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

SUFLAVE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Suflave, and when can generic versions of Suflave launch?

Suflave is a drug marketed by Braintree Labs and is included in one NDA.

The generic ingredient in SUFLAVE is magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SUFLAVE?
  • What are the global sales for SUFLAVE?
  • What is Average Wholesale Price for SUFLAVE?
Summary for SUFLAVE
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for SUFLAVE
What excipients (inactive ingredients) are in SUFLAVE?SUFLAVE excipients list
DailyMed Link:SUFLAVE at DailyMed
Drug patent expirations by year for SUFLAVE
Drug Prices for SUFLAVE

See drug prices for SUFLAVE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SUFLAVE
Generic Entry Date for SUFLAVE*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
NDA:
Dosage:
FOR SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SUFLAVE

SUFLAVE is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SUFLAVE is ⤷  Sign Up.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting SUFLAVE

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree Labs SUFLAVE magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate FOR SOLUTION;ORAL 215344-001 Jun 15, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.